Eiming Angke - B (01541.HK) announced that the group's independently developed IMM0306 (a novel innovative drug consisting of a bispecific antibody targeting CD47xCD20) has successfully completed its first patient administration in the phase Ib clinical trial for treating neuromyelitis optica spectrum disorders, with no adverse events reported.
宜明昂科(01541.HK)IMM0306的IB期臨床試驗完成首例患者給藥
The first patient administration of the IB phase clinical trial of Yiming Anke (01541.HK) IMM0306 has been completed.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
[2025.2] How should NVIDIA's performance be viewed? The key indicator to watch for short-term stock prices is this.
NVIDIA has been one of the best-performing Technology giants in the US stock market over the past two years, and since 2024, its stock price has experienced sig
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th